Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01869725 · ClinicalTrials.gov registry record · Phase 2

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

A Phase 2 study of Neuroblastoma and Neuroendocrine Tumor, sponsored by Sue O'Dorisio.

Completed
Registry status
Phase 2
Development phase
68
Enrollment target
1
Study location

NCT01869725 is a Phase 2 study of Neuroblastoma and Neuroendocrine Tumor that has completed, run by Sue O'Dorisio. The registered enrollment target is 68 participants, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01869725, a Phase 2 study of Neuroblastoma and Neuroendocrine Tumor, has completed, sponsored by Sue O'Dorisio.

COMPLETED
Registry status
Phase 2
Development phase
68 participants
Enrollment target
1
Study location

Study Summary

This clinical trial studies gallium Ga 68-edotreotide positron emission tomography (PET)/computed tomography (CT) compared with indium In 111 pentetreotide plus contrast-enhanced CT (or MRI) in diagnosing patients with neuroendocrine tumors and other somatostatin receptor positive tumors. Diagnostic procedures, such as gallium Ga 68-edotreotide PET/CT, may help find and diagnose somatostatin receptor positive neuroendocrine tumors. It is not yet known whether Ga 68-edotreotide PET/CT is as effective as indium In 111 pentetreotide plus contrast-enhanced CT (or MRI) in diagnosis and staging of patients with neuroendocrine tumors.

Conditions Studied

Neuroblastoma Neuroendocrine Tumor Somatostatinoma Childhood Medulloblastoma Adult Medulloblastoma

Interventions

  • PROCEDURE computed tomography
  • DRUG gallium Ga 68-edotreotide
  • PROCEDURE positron emission tomography/computed tomography
  • RADIATION indium In 111 pentetreotide
  • PROCEDURE contrast-enhanced magnetic resonance imaging

Study Locations (1)

Iowa

  • University of Iowa Hospitals and Clinics - Iowa City

Trial Details

FieldValue
Enrollment Target 68 participants
Start Date 2013-04-01
Est. Completion 2018-12-26
Phase Phase 2

Sponsor

Sue O'Dorisio

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01869725

The ClinicalTrials.gov registry entry for NCT01869725 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (71% lower). The listed sponsor is Sue O'Dorisio, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Neuroblastoma appearing as the primary indexed condition, and to 5 interventions - of which computed tomography is the first listed.

NCT01869725 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.

Frequently Asked Questions

What is clinical trial NCT01869725 about?

NCT01869725 is a clinical study titled "Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT". This clinical trial studies gallium Ga 68-edotreotide positron emission tomography (PET)/computed tomography (CT) compared with indium In 111 pentetreotide plus contrast-enhanced CT (or MRI) in diagnosing patients with neuroendocrine tumors and other somatostatin receptor positive tumors. Diagnostic...

What is the current status of trial NCT01869725?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2013-04-01. Estimated completion is 2018-12-26.

What conditions does trial NCT01869725 study?

This clinical trial studies the following conditions: Neuroblastoma, Neuroendocrine Tumor, Somatostatinoma, Childhood Medulloblastoma, Adult Medulloblastoma.

What interventions are being tested in trial NCT01869725?

The interventions under investigation include: computed tomography (PROCEDURE), gallium Ga 68-edotreotide (DRUG), positron emission tomography/computed tomography (PROCEDURE), indium In 111 pentetreotide (RADIATION), contrast-enhanced magnetic resonance imaging (PROCEDURE).

Who is sponsoring clinical trial NCT01869725?

This trial is sponsored by Sue O'Dorisio, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01869725 being conducted?

This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neuroblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neuroblastoma

All registered trials for this condition

Neuroendocrine Tumor

All registered trials for this condition

Iowa

All trials with a study site in Iowa

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.